Lepu Medical Technologies announced recently to prepare the big issue of acquisition with estimated amount of ￥650 million to ￥1.2 billion and the acquisition target embraced cardiovascular drug enterprises and hospitals. Because the above issue needs to negotiate with correlated parties which exists uncertainty, so the company stock will start to be suspended in Jan. 25 and lasting a month for estimated time.
 

It is reported that Lepu regards the “quaternity of medical devices, medicine, removal medical care and medical service for cardiovascular industry chain of plateau form enterprise” as its strategic target and takes the cardiovascular diseases medical treatment as the core to build up the vertical structure of ecological close-loop. From last year, the company expanded its single business to medical devices, pharmaceutical, medical service and removal medical care successfully. Especially the removal medical care and medical service expanded very fast through inside to extension.

The company utilized the multi-level market positively to inject the vigor for its business. At present, its subsidiary Beijing Lepu Genetic Technology Co., Ltd is applying to list in Three Board. Lepu Genetic will establish the high-flux genetic sequencing platform for cardiovascular, also integrating the chain of cardiovascular molecular diagnosis， sales and service as well as the major special inspection for the third-party inspection service network. Meanwhile, Hainai Ming Shengda, its subsidiary has already listed in Three Board which will assist Lepu broaden its sales channel and upgrade its market occupancy.